Mar 14, 2023 / 03:15PM GMT
Luke England Sergott - Barclays Bank PLC, Research Division - Research Analyst
Good morning, everybody. Luke Sergott from Barclays to cover life sciences tools and diagnostics. With me I have the pleasure of meeting John Gilardi, IR and Roland Sackers, CFO of Qiagen. I guess, to kick it off, just kind of go over the high, real high points of the quarter. What you guys are seeing from a demand perspective and then how that's really progressing versus what you guys were expecting?
Roland Sackers - Qiagen N.V. - CFO, MD & Member of Management Board
Sure. First of all, thanks for having us, and thanks for organizing, nice weather, we clearly deserve that. Yes, as you all know, we clearly finished the year '22 quite strong, not only the year, but also particularly in the fourth quarter, had a strong finish, particularly on the non-COVID growth rate, overall good growth rate. I think we were very pleased that all our [platforms] delivered on what we were expecting and adding to the market. And I know that some investors clearly had some concern about
Qiagen NV at Barclays Global Healthcare Conference Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers